Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GRAS Security Details
Share Structure
Market Value1 $36,945 a/o Dec 11, 2014
Shares Outstanding ............369,452,534 a/o Mar 04, 2014
Float .......................Not Available
Authorized Shares............. Not Available
http://www.otcmarkets.com/stock/GRAS/profile
The Company sells grassfed beef to grocery store chains throughout the southeast United States.
Market Cap
93.7 K
Shares Outstanding
937.4 M
Beta
6.8
SFOR Security Details
Share Structure
Market Value1 $59,412 a/o Dec 11, 2014
Shares Outstanding .............594,124,552 a/o Nov 12, 2014
Float ..........................45,000,000 a/o Sep 15, 2014
Authorized Shares............... 1,500,000,000 a/o Sep 15, 2014
http://www.otcmarkets.com/stock/SFOR/profile
StrikeForce Technologies provides a suite of online products that help prevent cyber theft and data breaches by protecting customers, employees and partners
Market Cap
59.4 K
Shares Outstanding
594.1 M
Beta
9.1
SHMN Security Details
Share Structure
Market Value1 $267,615 a/o Dec 11, 2014
Shares Outstanding .............535,230,071 a/o Jun 30, 2014
Float .........................89,474,492 a/o Dec 31, 2013
Authorized Shares.............. 1,000,000,000 a/o Jun 30, 2014
http://www.otcmarkets.com/stock/SHMN/profile
SOHM, Inc. is a generic pharmaceutical manufacturer
Market Cap
267.6 K
Shares Outstanding
535.2 M
TNEN Security Details
Share Structure
Market Value1 $74,304 a/o Dec 11, 2014
Shares Outstanding ................371,518,965 a/o Oct 31, 2014
Float ...........................41,343,559 a/o Nov 11, 2013
Authorized Shares .................2,500,000,000 a/o Jul 31, 2014
http://www.otcmarkets.com/stock/TNEN/profile
Market Cap
47.2 K
Shares Outstanding
235.8 M
ARIO Copy pasted from my Etrade account..
-0.0001
-99.00%
-$2,905.65......MY INTIAL INVESTMENT
29,350,000
$0.0001
-$2,949.55
-99.01%
$29.35...........IS NOW
AND FROM IBOX.....
Ameriresource Techno (ARIO)
0.000001 ? -0.000009 (-90.00%)
Volume: 1,500,513 @ 2:37:50 PM ET
Day's Range
0.0001
0.000001 - 0.000001
ARIO Detailed Quote
Wiki
PLEASE GET A PICTURE OF THIS IBOX.....
Dec 4, 2014 Greenfield Farms Food, Inc. and Its Wholly-Owned Subsidiary Carmela's Pizzeria Complete Implementation of Online Ordering System and Start Development of Carmela's Mobile App
Marketwired
Dec 2, 2014 Greenfield Farms Food, Inc. and Its Wholly-Owned Subsidiary Carmela's Pizzeria Complete Final Plans of New Location With Drive-Through Concept and Provide Update on Franchise Program
Marketwired
Oct 29, 2014 Greenfield Farms Food, Inc. and Its Wholly-Owned Subsidiary Carmela's Pizzeria Enter Into a Preliminary Agreement With SoFran, LLC. to Develop Nationwide Franchise Program
http://www.otcmarkets.com/stock/GRAS/news
MEDIPURE PHARMACEUTICALS INC CSE:MDH
needs a board
http://www.medipurepharmaceuticals.com/#
Medipure Holdings Commences Trading on the Canadian Securities Exchange
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov 10, 2014) - Medipure Holdings Inc. ("Medipure," or "the Company") (CSE:MDH) is pleased to announce that, effective today, the Company's common shares have commenced trading on the Canadian Securities Exchange under the ticker symbol 'MDH.'
http://finance.yahoo.com/news/medipure-holdings-commences-trading-canadian-130000090.html;_ylt=AwrBEiIA6YRUljcARUDQtDMD
Vodis Innovative Pharmaceuticals Inc.(CNSX:VP)
NEEDS A BOARD
http://vodis.ca/
T-Bird Pharma Inc, a Canadian pharmaceutical company, is considered the first in British Columbia to become a publicly traded medical marijuana firm. The company’s primary subsidiary, Thunderbird Biomedical Inc, is also one of the first in Canada to get a production license under the country’s Marihuana for Medical Purposes Regulations (MMPR).
Producing premium high-grade medicinal marijuana, T-Bird Pharma currently has a portfolio of more than 60 cannabis strains. This includes some well-known strains such as Island Honey, Blue Gold, and Pink Kush.
T-Bird’s alpha cannabis facility is operated by Thunderbird Biomedical and is situated in Saanich, Victoria. The facility covers 3,178 square feet, which may produce and sell – as per its Health Canada license – a maximum of 243 kg of dried marijuana. Thunderbird Biomedical is the fifth Canadian company to obtain this license.
A second facility of T-Bird Pharma is also located in Victoria, British Columbia. Of this 43,500-square foot facility, some 28,966 square feet will be for floor space and there is also an option for a mezzanine space of 14,500 square feet. Thunderbird has started infrastructure preparations in this facility, aiming to have Health Canada inspect it by the first quarter of 2015.
T-Bird Pharma Inc was founded in 2007 under the name Firebird Capital Partners. It also operated as Firebird Energy, Inc, exploring properties of natural gas and oil in Western Canada. After a recent reverse takeover, the company became T-Bird Pharma Inc in August 2014.
T-Bird Pharma is now traded as TPI in the TSX Venture Exchange, having a market cap of CAD 6.95 M.
Key executives at T-Bird Pharma include Founder and CEO Robert Gagnon, VP of Operations Rick Morris, VP of Quality Assurance Karen Parent, and CFO Chris Taylor.
http://www.bestmedicalmarijuanastocks.com/t-bird-pharma/
Cannabics Pharmaceuticals, Inc. is a U.S.-based company focusing on the development of and commercialization of sophisticated, advanced medicines, food supplements, therapies, and administration routes based on cannabinoids, the active ingredients and naturally occurring compounds found in unique, diverse strains of the cannabis plant.
Cannabics Inc. is a US based company founded in 2012 by a group of researchers from the fields of molecular biology, cancer research and pharmacology. The company’s research and development laboratories are located in Israel.
Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain. ( 5th November 2014 ) Link
Cannabics Pharmaceuticals Receives Cannabinoid R&D Lab Certification in Israel. ( 19th October 2014 ) Link
Just booked our trip to the Marijuana Business Conference and Expo in Vegas.
Cannabics Pharmaceuticals, Inc. Attains GMP Compliance, Prepares for First Clinical Study of Cannabics SR ( 25th September 2014 ) Link
Cannabics Pharmaceuticals recruits two former senior Teva Executives to its Advisory Board. (20th August 2014) link
On July 31st, 2014, Cannabics Pharmaceuticals Inc. successfully filed its exclusive Patent Application with the US Patent & Trademark Office (USPTO), which covers the proprietary technology developed by its team of experts for its product "Cannabics SR" a sustained release medical cannabis capsule which was designed specifically for oncology patients as a palliative care therapy. Simultaneously this Patent was filed with the PCT division of the Israeli Patent Office (ILPO) in order to provide International IP protection.
Cannabics Pharmaceuticals Inc, is now traded in the OTCQB market with the symbol CNBX. (20th June 2014)
http://www.cannabics.com/news-1/
Tauriga Sciences Inc. Progresses Towards Launch of Its Topical Medicinal Cannabis Creams Branded as Topicanna
7:00 AM ET 11/25/14 | GlobeNewswire
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or "the Company"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today updated shareholders about the upcoming launch of its proprietary topical medicinal cannabis creams to be branded as Topicanna. Several steps remain until an official launch is practical, however management is working diligently to complete these important steps; such steps are crucial to both the long term success and viability of the product line. These steps include: qualifying and testing oil with high cannabidiol (CBD) content from licensed suppliers, selecting the oil and scaling up the manufacturing process. The Company is hopeful that it can successfully launch its Topicanna product line within the next 60 days.
Many people who have used topical cannabis creams have reported decreased musculoskeletal pain without narcotic effects. The Company is currently developing two distinct Topicanna products: one which will contain ingredients to better penetrate to the joints, and one that will contain ingredients that have been successfully used for dermatological conditions. Tauriga's products will be offered in the United States (in compliance with all applicable medical marijuana regulations) and potentially in Japan pursuant to the recently announced MOU with Tokyo-based iFLOW Ltd ("iFLOW"). Medical marijuana law in Japan requires that products use oil that has been extracted from the stalk of the cannabis plant and that is necessarily higher in CBD and low in THC, hence providing potential wellness and healing properties without psychoactive effects.
Tauriga is also finalizing its formulation for its CannaCaviar soft gels using high-CBD, low-THC oil that has been extracted from the stalk of the cannabis plant. CannaCaviar is included in the recently announced MOU.
The Company is genuinely excited to complete these above-mentioned final steps that precede the launch of its Topicanna and soft gel products. The Company will take all necessary steps to ensure that it is always in compliance with the governing laws of each state, country and jurisdiction in which it plans to market its topical medicinal cannabis line. The Company plans to issue an additional press release to shareholders, once the product is complete and ready for launch.
In addition to the planned launch of the Topicanna and CannaCaviar lines, Tauriga is developing an e-commerce website (www.taurigastore.com) to sell its non-cannabis containing line of natural wellness dietary supplements. These natural supplements include IndiCalm, a relaxant and anxiolytic based on L-theanine; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and EndoCannabinoid Omega-3 Support (or MendOCan), a highly pure, potent and palatable Omega 3 supplement. Interested customers will be able to purchase these cannabis-free products online when the site is launched before the end of the year.
Tauriga Sciences Inc. Introduces First Cannabis Complements Product In Colorado July 31, 2014
We look forward to introducing additional Tauriga products to our guests and to expanding our relationship with Tauriga as we continue to provide Colorado-based businesses with marketing, advertising and entertainment services geared toward medical marijuana patients and recreational marijuana users.” In addition to introducing the non-cannabis-containing dietary supplements to the Colorado market, Tauriga, through its recently acquired subsidiary, Honeywood, is actively evaluating near-term options for expanding operations and production of cannabis-containing products into Colorado. These products include the established Doc Green’s brand of topical cannabis cream, as well as new products such as Vapura, a medicinal cannabis vapor cartridge that attaches to an e-cigarette battery and produces an effective and flavorful cannabis vapor. About Tauriga Sciences, Inc.: Tauriga Sciences, Inc. ( TAUG ) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses.
http://www.californiamedicalmarijuana.biz/tauriga-sciences-inc-introduces-first-cannabis-complements-product-in-colorado-yahoo-finance/
InMed Pharmaceuticals Inc., formerly Cannabis Technologies Inc, is a biopharmaceutical company that specializes in developing cannabis-based botanical and non-botanical therapies through the Research and Development into the pharmacology of Cannabinoids. The Company operates in two divisions: Drug Discovery & Development and Cultivation & Breeding. The Company is utilizing its Cannabinoid Drug Design Platform to identify bioactive compounds within the marijuana plant that interact with certain gene responsible for specific diseases. The Company's research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for glaucoma, cancer and angiogenesis, Inflammation and pain. The Company's botanical research division has begun the research and development into the individual strains and clones that will produce the raw material bases for future pharmaceutical research.
Headquarters:
409 Granville St Suite 350
VANCOUVER V6C 1T2
CAN
Cannabis Technologies Inc. Changes Name to InMed Pharmaceuticals Inc. October 16, 2014 10:40 AM
http://finance.yahoo.com/news/cannabis-technologies-inc-changes-name-144022896.html;_ylt=AwrBT4dL4nlUJDMAdFtXNyoA;_ylu=X3oDMTEzZnJ0Nm43BHNlYwNzcgRwb3MDOARjb2xvA2JmMQR2dGlkA1ZJUDUyM18x
INSYS Therapeutics, Inc. (NASDAQ: INSY) Dronabinol Oral Solution is an orally-administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol (THC), which may offer advantages over Dronabinol SG, including more consistent bioavailability, faster onset of action and more flexible dose titration. The FDA granted Insys Orphan Drug Designation for use of pharmaceutical cannabidiol, or CBD, for the treatment of both Lennox-Gastaut Syndrome and Dravet Syndrome, two rare forms of epilepsy in children, and for the treatment of glioblastoma multiforme, an aggressive and often incurable form of brain cancer. Insys plans to file an IND for CBD in the second half of 2014. The company recently submitted its NDA for Dronabinol Oral Solution, a novel formulation which has the potential to offer distinct advantages over existing generic capsules including a faster rate of absorption, more consistent blood levels, and the ability to titrate to effect.
FROM....
Online Medical Marijuana & CBD Dispensary Directory Provides Patients with User-Friendly Cannabis App to Identify Products, Various Strains & Dispensary Locations
53 days 2 hours 17 minutes ago - DJNF
CORAL SPRINGS, Florida, October 7, 2014 /PRNewswire/
METTRUM HEALTH ORD (MT: TSXV)
1.86 CAD +0.01 (+0.54%) 1.85 (x79) 1.96 (x12) 1.86 - 1.97 8,040
Copied from my Etrade account.
To much for me to buy. I am looking for a 200.00 dollar buy under .50 cents. And watch for dilution. Maybe add if no dillution over the months ahead.
Cheers
Verde Science has assembled an impressive team of scientists from highly technical disciplines including Bioprocess Technology, Nanotechnology, Molecular Virology and Immunology, Molecular Biology, Pharmacology and Medical Device Design. Our focus is the discovery of novel drugs and new treatment modalities, as well as cutting edge diagnostic devices and pharmaceutical delivery systems for the treatment of emerging diseases and contemporary medical issues where current treatments either do not exist or are inadequate.
An initial focus is on developing custom medicinal formulations from cannabinoids and THC compounds for the treatment of specific issues such as migraines, glaucoma, loss of appetite from cancer therapies, and numerous other medical issues.
Currently the company is working on starting a Research and Development initiative in Canada upon becoming licenced. In the meantime, the company is beginning a THC Pharmaceutical Development Program to be run through its alliance with the Institute of Chemical Technology in Mumbai, India. The program will include executing comprehensive research to develop specific, custom formulations and novel delivery mechanisms for cannabinoid and THC based drugs.
The Institute of Chemical Technology (ICT), Mumbai, is India’s premier chemical engineering and technology research institute. The institute is dedicated to training and research in various branches of Chemical Engineering, Chemical Technology, and Pharmacy
The Sterkem Pharma Group of Companies was established in 1974 and has continued to market quality pharmaceuticals for over a third of a century. The family based enterprise has been a brand leader for Anti-arthritic drugs viz. Inmecin (Indomethacin) and its allied products. Injectable formulations, both powder and liquid were among the first products marketed by Sterkem. Today their marketing domain includes Anti-arthritic, Antidepressants, Analgesics, Antibiotics, and a range of Gynaecological and Obstetric drugs in different formulations. The most recent additions to their range of products are Multi-Vitamins, Anti-oxidants and Nutritional Supplements that strengthen the immune system.
Verde Science plans to develop specific, custom formulations and novel delivery mechanisms for cannabinoid and THC based drugs for a variety of ailments including chronic pain, inflammation, migraines, seizures related to epilepsy, nausea associated with cancer treatment, and numerous others. The company then plans to then conduct clinical trials in Canada after it obtains its Canadian R&D license.
http://verdescienceinc.com/
URVape (http://www.urvape.com) is a Florida Corporation, wholly owned by FutureWorld Corp., based in Saint Petersburg, Florida. URVape manufactures, markets, and distributes electronic cigarettes, vaporizers, and accessories under the URVape brand name in the United States. It offers vaporizers and related products through its online store urvape.com, as well as through the company's wholesale, distributor, and retail programs. Operating on the idea of open source technology and innovation, the URVape vision is to bring standardized versatility to our customers by offering easily customizable vape pen solutions. URVape supplies avid vape enthusiasts and smokers with a sleek and sophisticated vaporizer that is both affordable and covetable. The Company already plans on adding a loose-leaf herb vape pen, wax vape pen and CBD oil to the mix of offering. The Company is setting the stage for a leading position within the world's 200 billion dollar tobacco market and the multibillion dollar cannabis industry.
http://www.urvape.com/
?FutureWorld (FWDG) to Deposit 10,000,000 HempTech Shares In Shareholders' Trust for Spin-Off
[GlobeNewswire] - ST. PETERSBURG, FL -- FutureWorld Corp. (OTCQB; FWDG), a leading provider of advanced technologies and solutions to the global cannabis industry, announces today that it is depositing 10,000,000 shares ...
?FutureWorld (FWDG) to Deposit 20,000,000 CB Scientific Shares In Shareholders' Trust for Spin-Off
[GlobeNewswire] - Denver, Colorado -- FutureWorld Corp. (OTCQB; FWDG), a leading provider of advanced technologies and solutions to the global cannabis industry, announces today that it is depositing 20,000,000 shares of ...
?FutureWorld (FWDG) Subsidiary CB Scientific Consolidates Global Cannabis THC & CBD Personal Analytic
[GlobeNewswire] - ST. PETERSBURG, FL -- FutureWorld Corp. (OTCQB;FWDG), a leading provider of advanced technologies and solutions to the global cannabis industry, announces that it has purchased controlling ownership interest ...
?FutureWorld (FWDG) Subsidiary FutureLand Properties, LLC Closes on 237 Acres South of Denver
[GlobeNewswire] - ST. PETERSBURG, FL -- FutureWorld Corp. (OTCQB: FWDG), a leading provider of advanced technologies and solutions to the global cannabis industry, announces that its wholly-owned subsidiary, FutureLand ...
?FutureWorld (FWDG) to Construct Large Cannabis Cultivation Greenhouse for Clients in Colorado
[Business Wire] - FutureWorld Corp. , announces today that the Company is to finance and build a 3500+ plant cannabis cultivation greenhouse for a client on 237 acres of property being purchased by the Company, through FutureLand properties LLC, and leased back to the client.
http://www.futureworldcorp.com/news-events
Corporate Info
FutureWorld Corporation
3637 4th Street North, #330
Saint Petersburg, FLORIDA (FL) 33704
Phone: (727) 474-1816
The American Hemp Trading Company, Inc. Business Import And Export
http://www.lookupbook.com/us/fl/birmingham/business-import-and-export/the-american-hemp-trading-company-inc
“Agritek Venture Holdings, Inc.,” which holds all land acquisitions and leases as well as “The American Hemp Trading, Inc.,” for hemp based beverages and products.
http://ir.agritekholdings.com/
Provisional License for Cultivation Facility in Nevada "Green Zone" for Tenant My Life Organics
http://content.stockpr.com/_news/mediswipe/2014-11-05_Agritek_Holdings_Inc_Announces_Grant_of_Provision_1084.pdf
WEBSITE
http://agritekholdings.com/wellness-products/
Easton Pharmaceuticals Secures Financing Commitment Regarding Medical Pot
October 21, 2014 1:53 am·0 comments
Easton Pharmaceuticals Inc. (OTC: EAPH) announces it has sourced out and secured financing commitment for the full amount owed on its option to purchase its entire ownership interest on its Canadian medical marijuana Initiative.
The financing commitment including cash the company currently has in hand is over and above what is required for Easton to close on its exclusive option agreement to purchase up to 49% of its Canadian medical marijuana business and initiative that has received a letter to build from Health Canada under the country’s new MMPR system. The financing commitment is from a private Canadian accredited investor. The funding is to be forwarded to the Company upon receiving a Health Canada MMPR license as per the option agreement signed in June of this year. Complete terms to be disclosed at that time. The company is now focusing on reviewing agreements executed in June of this year when it purchased its option as well as receiving a detailed progress report on the status of the licensing process. Unfortunately, Easton is not able at this time to disclose any additional details on the MMJ property including any pictures of the facilities, which was previously stated in error.
Carla Pepe, CEO of Easton Pharmaceuticals commented, “We are pleased to have received the financing commitment which allows us to purchase and close on our entire option once the license has been received. The financing allows us to focus on other initiatives while we await a final license along with its partners. The commitment is solely for the Canadian medical marijuana initiative and is not to be utilized on any other business segments. Easton will continue to pursue other additional financing to further its other initiatives including its OTC products, its 2 drugs where it owns 50% and 10% of 2 drugs respectively, as well as having cash on hand to advance on other possible initiatives within the State of California it hopes to soon finalize and announce. This also includes its current partnership with AMFIL Technologies who have shipped an mPact-GROzone Antimicrobial System to a large grower in the State of Colorado and others.”
Although the industry wide licensing process with health Canada is progressing slower than expected due to the large amount of applications and the new security measures that were implemented for all applicants, management believes as do others in the industry, that only companies who currently have a letter to build, will ultimately receive licenses with no more than 50 licenses in total being approved by health Canada. Health Canada projects the Canadian medical marijuana industry will grow in the Billions in the next few years which is approved nationally. The current liberal minority government has made full legalization of Cannabis as its platform.
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://www.marijuanastocksreport.com/easton-pharmaceuticals-secures-financing-commitment-regarding-medical-pot/
About Neutra Corp.
Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By delivering a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete GW Pharmaceuticals (OTCBB:GWPRF), Growlife Inc. (OTCBB:PHOT) and Medbox Inc. (OTCBB:MDBX) and other leaders in the fast-growing, billion-dollar U.S. cannabis industry. For investing information and performance data, please visit www.neutracorp.com.
Neutra Corp. (OTCBB:NTRR) has set its sights on Texas, the country’s largest remaining market with no medical cannabis provisions and a state experts say could lead the nation as a model of reform.
http://markets.financialcontent.com/ir/?Ticker=NTRR&GUID=28748793&Module=MediaViewer
Medican Systems Inc.
Medican Systems is the wholly owned operating subsidiary of Medican Enterprises and is the operating arm of the company’s Medical Marijuana Cultivation and Research Facilities.
Medican Systems is a pioneer and seeks to become one of Canada’s first commercially Licensed Producers of Medical Marijuana (“MMJ”) under the new program Marijuana for Medical Purposes Regulation (MMPR).
Through an in house team of R&D professionals and leading Horticultural Ph.Ds, Medican will conduct evidence-based scientific research to advance the medical marijuana industry.
Medican will focus on cultivating 5 strains of Cannabis with standardized potencies and verified purity.
High THC / Low CBD
Medium THC / Low CBD
Medium THC / Medium CBD
##Low TCH / High CBD
Corporate Contact Information:
MediCan Enterprises Inc. Head Office
3440 E Russell Road
Las Vegas, NV 89120
? +1.702.826.3365
http://www.medicaninc.com/category/news-releases/
http://ih.advfn.com/p.php?pid=news&symbol=NO%5EMDCN
Crown Marketing Pharmaceuticals is a pioneer in the field of Controlled Drug Delivery Technology (CDDT), and is currently in the process of introducing its patented product to the market. Poised to become one of the major players in the pharmaceutical industry, Crown’s technology allows for significant cost efficiencies in the commercial manufacturing process over competing drug delivery technologies, and can play a crucial role in lifecycle management for existing patented medications. Crown’s CDDT can maintain targeted plasma concentrations and minimize peak-to-trough variations in drug concentration, all while keeping manufacturing costs at a manageable level compared to currently-available complex diffusion matrices, has the potential to revolutionize the pharmaceutical industry.
http://crowncddt.com/technology/intellectual-property//
CONTACT INFORMATION
4350 TEMPLE CITY BLVD
El MONTE,CA 91731
E-mail: info@cwnmusa.com
http://www.cannabiskinetics.com/brands/
https://www.facebook.com/REMBEV
News for Cannabis Kinetics Corp (CANK)
Fri, Oct 31, 2014
6:15 AM Cannabis Kinetics Corp. Secures Financing - Marketwired
Fri, Oct 24, 2014
8:34 AM Cannabis Kinetics Corp. to Supply Monarch Brand Coco Coir to Established Retail and Grow Facility Management Company - Marketwired
Mon, Oct 06, 2014
9:06 AM Neutra Corp Doubles but Cannabis Stocks Move Largely Lower Last Week - Accesswire
6:16 AM Cannabis Kinetics Corp. Places First Order to Import Coco Coir Growing Medium - Marketwired
Tue, Sep 30, 2014
6:16 AM Cannabis Kinetics Corp. Sets National Distribution Strategy for Monarch Branded Coco Coir Growing Medium - Marketwired
Fri, Sep 26, 2014
2:22 PM Cannabis Kinetics Corp. Enters Exclusive Global Distribution Agreement for Coco Coir Soil Additive - Marketwired
Sun, Sep 21, 2014
6:23 PM Cannabis Kinetics Corp. to Acquire Established Hydroponics and Indoor Garden Supplier - Marketwired
Thu, Sep 18, 2014
9:11 PM Cannabis Kinetics Corp. Outlines Mission Statement and Diversified Growth Opportunities Within the Rapidly Expanding Marijuana Sector - Marketwired
http://www.cannabiskinetics.com/investors/
Cannabis Kinetics Corporation
3240 W. 71st Avenue, Unit No. 5
Westminster, Colorado 80030 USA
Telephone: 888.668.2280
Pharmos Corporation (Pharmos) is a biopharmaceutical company that discovers and develops therapeutics to treat a range of metabolic and nervous system disorders, including gout, disorders of the brain-gut axis, pain/inflammation and autoimmune disorders. Pharmos owns the rights to both R and S Tofisopam. These are the two enantiomers of racemic tofisopam that has been used outside the United States. The Company's primary focus is on the development and partnering of Levotofisopam and Dextofisopam. The Company's product Dextofisopam is used for the treatment of irritable bowel syndrome (IBS). Dextofisopam is the R enantiomer of racemic tofisopam. Levotofisopam is the S-enantiomer of the racemic mixture RS-tofisopam.
http://pharmoscorp.com/
Headquarters: SUITE 301, 99 WOOD AVE. SOUTH
ISELIN, NJ 08830
ABOVE INFO FROM ETRADE...
Parkinson’s Disease & Off-Episodes
Parkinson’s disease is the second most common degenerative brain disease. One percent of 60 year olds and 4% of 80 year olds have PD. Dysfunction and loss of dopamine neurons throughout the brain, particularly in the substantia nigra, cause the cardinal symptoms of tremor, difficulty moving, shuffling gait, and postural instability. Disease symptoms manifest only after 60-80% of dopamine neurons in the substantia nigra have died; diagnosis most commonly occurs in the sixth or seventh decade of life. An estimated 4 to 6 million people worldwide have PD (about 1 million in the US alone) a number expected to reach 8.7 million by 2030.
http://www.cynapsus.ca/general.php?pid=7
Plandaí Biotechnology, Inc. intends to transform the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability currently in the market. Our headquarters are in Seattle, Washington, USA. Although we also have a global presence with offices in London, England and Nelspruit in the province of Mpumalanga, South Africa. This enables us to react more efficiently to any worldwide market changes as well as to any customer requirements.
Plandaí Biotechnology is the culmination of over ten years of research in the field of plant extracts. Its principle holdings consist of land, farms and infrastructure, totaling more than 8500 acres, in the province of Mpumalanga, South Africa.
Plandaí Biotechnology, Inc., through its wholly owned subsidiaries, farms over 7500 acres of luscious land in the Mpumalanga province of South Africa.
Plandai Biotechnology Collaboration Offers Opportunity to Produce a Non-Psychoactive Cannabis Product for Medical Research
http://finance.yahoo.com/news/plandai-biotechnology-collaboration-offers-opportunity-140000838.html
Plandai Biotechnology Cannabis Research Gets Green Light From Uruguay
http://finance.yahoo.com/news/plandai-biotechnology-cannabis-research-gets-140000013.html
http://www.plandaibiotech.com/products.html
Nuvilex Inc. (PINK:NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., will study the medical applications of marijuana (Cannabis sativa) and develop treatments for serious human diseases. The company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development.
- See more at: http://www.thcbiz.com/nvlx.html#sthash.aM33AyfH.dpuf
WEBSITE
http://client.irwebkit.com/Nuvilex
Cannabis Science, Inc. is engaged in the research and development of medical marijuana. The company works on phytocannabinoid science, targeting illnesses to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The company focuses on creating cannabis-based medicines...
http://www.thcbiz.com/marijuana-stocks.html
The Science of Cannabinoids
http://cannabisscience.com/about-cbis/the-science-of-cannabinoids
3B A/S
Dutch Cannabis Producer Sets Up In Canada
The Canadian arm of Bedrocan BV, the sole supplier of medical marijuana in The Netherlands, has been licensed by Health Canada to begin supplying Canadian patients.
The company, Bedrocan Canada, plans to begin filling orders by late February, with product imported from its Dutch facilities. It aims to begin local production by late 2014.
The President of Bedrocan Canada is Marc Wayne, former Business Director of the Canadian Consortium for the Investigation of Cannabinoids (CCIC), an educational organization that has worked closely with Bedrocan in the past.
“We are excited to introduce Bedrocan’s values and varieties to Canadians. Our Health Canada license and partnership with Bedrocan BV will enable Canadian patients to access high quality, standardized strains of medicinal cannabis used for 11 years in the Dutch medicinal cannabis program,” said Wayne in a release this morning.
Under a new program (MMPR) that passed last summer, the Canadian government has created a commercial industry for medical marijuana, which is set to replace the old program (MMAR) fully by April 1st.
Patients who were once allowed to grow for themselves will be required to instead register with a commercial producer and purchase their medicine online.
http://www.leafscience.com/2014/01/14/dutch-cannabis-producer-sets-canada/
GB Sciences Las Vegas Cultivation Facility
GB Sciences Nevada - Cultivation Facility
http://vimeo.com/110499518
GB Sciences Nevada, LLC (GBSN), is working to provide the citizens of Nevada with the highest-quality cannabinoid treatments. In June, 2014, GBSN received a special use permit to operate a cultivation center in Clark County, Nevada—the state’s first local jurisdiction to accept and approve applications for cannabis-related businesses. In November, 2014, the State of Nevada gave its approval
This 28,432-square-foot facility will contain 20,000 square feet of cultivation space to house GB Sciences’ proprietary technology system for growing medical-grade cannabis in the TissueBLOX™ (for immature plantlets), GrowBLOX™ (for mature plants), and CureBLOX™ (to ensure safe, efficacious drying). In addition, the facility will feature a 2,500-square-foot conversion lab for extracting and post-processing oil-based cannabinoid therapies, a security control room, a packaging room, employee facilities, and management offices.
LAS VEGAS, Nov 6, 2014 GrowBLOX Sciences, Inc., (“GB Sciences“) (GBLX), announced today that its majority-controlled Nevada applicant, GB Sciences Nevada, LLC, has received Nevada State approval to proceed with its special use permit to establish and operate a medical marijuana cultivation facility in Clark County.
GB Sciences Nevada did not receive approval from the State of Nevada for two dispensaries for which it had received approvals from Clark County and The City of Las Vegas. This puts the Company in a position similar to others who received state approval, but were denied or not yet approved by one or both of the other jurisdictions. It is unclear when, how, or if the inconsistencies between the state, city and county approvals will ultimately be resolved. While it would have been beneficial to have received the state dispensary approvals at this time, it does not detract from GB Sciences’ primary mission.
“Although we do not mean to understate the immediate commercial value of the cultivation license we were granted, our primary focus in obtaining the license was to enable the clinical research efforts we have planned, and to continue our other research initiatives into plant genetics, curing techniques, and the development of strains that are effective for particular diseases,” said GB Sciences, Inc., CEO Craig Ellins. “Without the license that was granted today, we could not pursue our mission of providing safe, consistent medication for the literally thousands of patients who need it. As a biopharmaceutical company, GB Sciences will create value through developing, patenting and branding innovative treatments; especially in ‘orphan’ disease categories where the ill have few if any treatment options.”
http://gbsciences.com/gb-sciences-las-vegas-cannabis-cultivation/
GB Sciences Partnerships
GB Sciences’ turnkey solutions facilitate entry into the emerging cannabinoid therapy marketplace. Our partners provide capital and local personnel, while we help them navigate through the state application process and set them up with our trademarked production and retail system. Our system is flexible and can be scaled to meet the needs of each partner’s local patient base.
Our Company
GrowBLOX Sciences, or GB Sciences, Inc. (OTCQB: GBLX), is a medical cannabis research and development company that offers solutions for the commercialization of cannabis and cannabis-based products to treat medical conditions and relieve their symptoms.
We are working hard to become the trusted brand of technology that empowers patients with access to the benefits of medicinal-grade cannabis, and to become the trusted producer of consistent and efficacious medicinal cannabis strains and product lines. Our products are manufactured with clinical, laboratory precision to ensure a high quality and consistency.
Significant milestones we have reached include:
Secured special use permits for a dispensary and cultivation facility in Clark County, Nevada
Filed for two dispensary locations in Las Vegas, Nevada
Secured Letter of Intent with First Security Bank of Nevada
Established subsidiary in Florida in anticipation for favorable upcoming legislative vote
Acquired 20% equity of LaurelCo LLC medical marijuana operations in Illinois and a 10% royalty on any products created with the GrowBLOX™
Key Projects in the Works
Finalizing a partnership in New York for dispensary and cultivation operations
Developing infrastructure in Puerto Rico in anticipation of favorable legislation
Obtaining FDA Approval of pharmaceutical product line
http://gbsciences.com/
InMed Pharmaceuticals is a clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
InMed is utilizing its proprietary "Intelligent Cannabinoid Drug Design Platform" to identify new bioactive compounds within the cannabis plant that interact with certain gene responsible for specific diseases.
Our Proprietary Platform Technology, Product pipeline and accelerated drug discovery/development pathway are the fundamental value drivers of the Company.
InMed's botanical research team has begun to develop the individual strains & clones that will produce the raw material bases for future pharmaceutical research.
Pipeline
CTI-085
Is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma. InMed has identified our lead composition (CTI 085) through 12 months of discovery and preclinical studies that showed efficacy in lowering intraocular pressure (IOP) in animal models. Cannabinoids have IOP lowering effects, thus, they have therapeutic potential in the treatment of glaucoma. Our objective for this therapy was to develop a safer; cannabis based topical anti-glaucoma formulation without systemic side effects.
CTI-091
Is a proprietary mixture of cannabinoids and non-cannabis based active ingredients designed for the relief of joint pain and swelling associated with arthritis and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation. We are currently developing an innovative new delivery system to enhance retention and absorption of the key active ingredients around the target site to relieve joint pain and swelling.
Press Releases
October 23, 2014 InMed Commences Development of Proprietary Drug Delivery System
October 21, 2014 Cannabis Technologies Inc. Now Trading as InMed Pharmaceuticals Inc.
October 16, 2014 Cannabis Technologies Inc. Changes Name to InMed Pharmaceuticals Inc.
September 09, 2014 Cannabis Technologies Appoints Peter Huang as Senior Bioinformatician
August 18, 2014 Cannabis Technologies Announces Second Therapy-CTI 091
July 16, 2014 Cannabis Technologies Announces Momentum PR
June 24, 2014 Cannabis Technologies Announces Glaucoma Therapy Entering into Phase 1 Clinical Trials
June 10, 2014 Cannabis Technologies Appoints Dr. Tarek S. Mansour, Ph.D. to Scientific Advisory Board
June 04, 2014 Cannabis Technologies Commences Trading on OTCQB
May 21, 2014 Cannabis Technologies Commences trading on CSE
July 18, 2014
2014 CTV Morning Live
Publisher: CTV News
http://www.cannabis-tech.com/s/media.asp?ReportID=665288&_Type=Media&_Title=2014-CTV-Morning-Live
Novus Acquisition & Development Corp. is a venture firm specializing in small to midsize companies. The firm seeks to acquire merge or joint venture with small to midsize companies in the healthcare/MMJ industry that seek capital for expansion or roll up acquisition. We prefer to fully/ partially acquire or hold membership on boards of directors in our portfolio of companies. We have diverse structure in our investments and Our primary focus is not to run the company but to make sure that there is fiscal responsibility that leads to growth.
Company Profile
Novus is comprised of seasoned Wall Street/ Healthcare veterans that have focused its business model in Health and Wellness from physicians to patient treatment in the medical cannabis industry (MMJ). Management and its Board of Directors areas of expertise is diversified in Healthcare Management, Physicians Education, HMO, Pharma R&D, Compliance and Business Development. Since MMJ is not federally approved, NDEV focus is to mitigate risk through the development of our web portal, established regulatory protocol in the doctor patient relationship as a treatment option. NDEV is not in the business in cultivating, handle, transport grow, extract, dispense put up for sale, put on the market, vend, deliver, supply, circulate, trade, cannabis or any substances that violates the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws.
Novus Aquisition & Development
http://www.novusqc.com/novus-services/
Next Gen is a diversified Canadian public company which focuses on investing in the Medical Marijuana, Industrial Hemp and Alternative Medicine sectors.
The Company’s Medical Marijuana/Industrial Hemp divisions are working towards branding Next Gen as the go-to Canadian public company for Legal Marijuana and Industrial Hemp investment.
Next Gen is actively reviewing new business proposals in the Medical Marijuana and Industrial Hemp industries.
http://www.nextgenmetalsinc.com/greenrush/index_NHome.htm
Cannabis Therapy Corp specializes in proprietary identification, extraction, production, and marketing of pharmaceutical-grade cannabinoids and cannabinoid-containing products for the food science, pharmaceutical, nutritional supplement and nutraceutical industries.
http://cannabistherapy.com/
Offering end-to-end integration from plant cultivation to product manufacturing, Cannabis Therapy Corp will develop its primary business of manufacturing and marketing pharmaceutical level cannabinoid extracts and products for use across a broad spectrum of consumer, industry and research applications.
Cannabis Therapy Corp is positioning itself to meet this demand with a supply of biopharma grade cannabis extracts, cannabinoids and cannabinoid formulations. Specializing in proprietary cannabinoid extraction, using processes from the biopharma industry, Cannabis Therapy Corporation is uniquely well-positioned to supply pharmacy-grade, isolated cannabinoids and cannabinoid products
Cannabis Therapy Corp is focused on:
•Becoming the leading provider of gold standard, pharmacy-grade cannabinoids and innovative cannabinoid products.
•Rapidly integrating its products into fast-growing, high-return market segments.
•Positioning the Company to achieve long-term success in the exploding nutraceutical market.
•Generating earnings through the development of multiple synergistic revenue streams derived from proprietary products and services.
•Leveraging the Company’s extensive experience in the creation of intellectual property and licensing models in order to secure and leverage IP where applicable.
•Achieving the goal of providing optimal returns for our investors
$EAPH Releases Update for Black Friday / Cyber Week Sales
TORONTO, ON–(Marketwired – Nov 26, 2014) – Easton Pharmaceuticals (OTC: EAPH) has in the past month taken steps to enter into the fast growing Vaporizer market. On Black Friday and Cyber Monday we will be offering a 25% to 40% discount on select products. 25% discounts will apply for premium branded items while 40% will apply to non premium products. We believe there is adequate current inventory to satisfy anticipated demand, but selling out is always a possibility.
http://marijuanastocks.com/eaph-releases-update-black-friday-cyber-week-sales/
http://www.eastonpharmaceuticalsinc.com/
Buy 1/2 ounce bottle of High Grade CBD (Cannabidiol) Rich Hemp Oil for only $129:
http://www.earthsciencetech.com/cbd-rich-hemp-oil/
About Mettrum
Mettrum™ is a Health Canada licensed producer of medicinal cannabis and is committed to ongoing research, regulatory compliance, producing quality products, and providing comprehensive customer service.
There is increasing belief that medical cannabis is an appropriate natural medicine for the treatment of a wide range of medical issues. Health Canada has recently implemented new regulations to improve access to medical marijuana patients Canada-wide. As a Licensed Producer, Mettrum operates in compliance with these regulations to meet the needs of our clients.The Mettrum™ team has decades of combined experience in the agri-pharma, distribution and technology industries. We've recently completed our research and production facility, and have received approval from Health Canada to be a Licensed Producer under the Marihuana for Medical Purposes Regulations.
http://www.mettrum.com/about/
http://www.realhemp.com/
Hello and thank you for visiting! This is an exciting time with the harvest season for hemp under way and the launch of a new store being planned. We will be stocking our shelves with the best hemp products available and want to be able to reach out to you and let you know when the store is opening. Subscribe below or connect to any of our social media links to receive any opening day specials and be the first to know when the Store is open
http://www.realhempstore.com/
http://www.organigram.ca/about/
At OrganiGram, it is our priority to ensure all of our clients have consistent and reliable access to the strains of their choice, issued from organic Cannabis plants as certified by Ecocert Canada. By combining advanced technologies and proven methods, we assure a high quality, secure and regulated source of condition-specific medical marijuana for patients and doctors in Canada that requires no irradiation or cold pasteurization.
All of our products are lab tested prior to packaging and are manufactured under strict controls and in conformance with the Good Manufacturing Practices of the FDA as well as the security directives as defined by the Office of Controlled Substances.